Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC) Meeting Abstract
| Authors: | Wong, W.; Sherman, E. J.; Kriplani, A.; Michel, L.; Zhi, I.; Hung, T. K. W.; Dunn, L.; Grewal, R. K.; Krishnamoorthy, G.; Ostrovnaya, I.; Katabi, N.; Fagin, J.; Pfister, D.; Ho, A. L. |
| Abstract Title: | Phase II study of PDR001 in combination with MAPK pathway inhibitors in patients with radioactive-refractory differentiated thyroid cancer (DTC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sep 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S1122 |
| Language: | English |
| ACCESSION: | WOS:001326612902547 |
| DOI: | 10.1016/j.annonc.2024.08.2012 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1931P -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
